May 28, 2015
A California federal judge Wednesday tossed a derivative shareholder suit accusing Allergan Inc.'s board members of improperly marketing the cosmetic drug Botox for off-label uses after a voluntary dismissal by the plaintiffs, who the pharmaceutical giant argued no longer had standing following an acquisition by Actavis PLC.
April 30, 2015
Allergan Inc. urged a California federal judge on Wednesday to toss a derivative shareholder suit accusing the pharmaceutical firm's board of improperly marketing the cosmetic drug Botox for off-label uses, saying plaintiffs lack standing to bring the case since they are no longer shareholders.